Tropifexor CAS No.: 1383816-29-2

for this product.

Introduction to Tropifexor CAS No.: 1383816-29-2

Tropifexor, also known as LJN452, is a novel and potent selective agonist of farnesoid X receptor (FXR). FXR is a nuclear receptor that plays a vital role in regulating liver and intestinal metabolism, bile acid synthesis, and lipid metabolism. Tropifexor is a next-generation FXR agonist that exhibits improved potency and selectivity compared to existing FXR agonists.

Tropifexor has shown promising results in preclinical studies and has the potential to treat various liver and metabolic disorders such as non-alcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and other rare cholestatic liver diseases.

Why Choose Tropifexor?

There are several reasons why merchants should choose Tropifexor:

1) Potent and Selective

Tropifexor is a highly potent and selective FXR agonist, meaning it can selectively activate the FXR pathway without affecting other nuclear receptors or causing off-target effects. Tropifexor has shown improved potency and selectivity compared to existing FXR agonists, making it a promising drug candidate for a broad range of liver and metabolic disorders.

2) High Efficacy

Tropifexor has demonstrated high efficacy in preclinical studies, including robust reduction in liver fat accumulation, improvement in liver fibrosis, and reduction in inflammation. In a phase 2 clinical trial for NASH, Tropifexor showed promising results in reducing liver fat, and phase 3 studies are currently underway.

3) Versatility

Tropifexor has the potential to treat various liver and metabolic disorders, including NASH, PBC, PSC, and other rare cholestatic liver diseases. This versatility makes Tropifexor an attractive drug candidate for pharmaceutical companies looking to develop therapies for these diseases.

4) High Safety and Tolerability

Tropifexor has shown a good safety profile in preclinical studies and has been well-tolerated in clinical trials. Tropifexor has not shown any significant adverse effects in patients, making it a safe and effective drug candidate.

Conclusion

In summary, Tropifexor is a novel and promising drug candidate for the treatment of various liver and metabolic disorders. Its high potency, selectivity, efficacy, versatility, and safety make it a sought-after drug candidate for pharmaceutical companies developing therapies for liver diseases. As a manufacturer, we are confident in the quality and effectiveness of our Tropifexor product and welcome inquiries from interested merchants.

Chemical Structure: Tropifexor

CAS No.: 1383816-29-2

 

Tropifexor(LJN-452;LJN452)

Catalog No.: URK-V590 Only Used For Lab.

Tropifexor (LJN-452, LJN452) is a novel highly potent, selective, orally acitive FXR full agonist with EC50 of 0.20 nM.

Biological Activity

Tropifexor (LJN-452, LJN452) is a novel highly potent, selective, orally acitive FXR full agonist with EC50 of 0.20 nM; shows no significant off-target activity (>10,000-fold selectivity for FXR) in a panel of targets, including TGR5 (>10 uM); demonstratesin vivo activity in rodent PD models, and shows potential for treatment of cholestatic liver diseases and NASH.
Steatohepatitis
Phase 2 Clinical

Physicochemical Properties

References

1. Tully DC, et al. J Med Chem. 2017 Dec 8. doi: 10.1021/acs.jmedchem.7b00907.

URK-V590 COA

URK-V590_DataSheet

URK-V590_SDS

 

Note: All products of Ureiko are only used for scientific research or drug certificate declaration, and we do not provide products and services for any personal use!

Why choose us?

• Our team of experts is always available to answer any questions and provide guidance when needed.
• Reliable good quality and very good credit standing are our principles, which will help us at a top-ranking position.
• If you're looking for the best Nuclear Receptor/Transcription Factor Library products on the market, look no further than our factory.
• We hope to stimulate the vitality of the company and strive to meet the needs of customers in order to achieve another leap forward for the company.
• We are dedicated to providing our customers with the highest level of customer service and support.
• Our company actively enters the overseas market and strives to develop new markets and new Tropifexor CAS No.: 1383816-29-2.
• We are constantly seeking ways to improve our products and services to provide even more value to our customers.
• Our excellent technology, stable products and sincere service have been recognized by our business partners all over the world.
• Our Nuclear Receptor/Transcription Factor Library products are used in a variety of industries, including pharmaceuticals, biotechnology, and agriculture.
• In today's increasingly fierce market competition, we are working hard to develop new products and new technologies in order to meet the ever-changing needs of users.

Hot Tags: tropifexor cas no.: 1383816-29-2, China tropifexor cas no.: 1383816-29-2, epigenetic library for epigenetic regulation of cell differentiation, inhibitors for drug resistance, epigenetic library for epigenetic suppression, inhibitors for pathogen recognition, inhibitors for bioavailability, epigenetic library for epigenetic analysis of chromatin structure